GenMark Diagnostics Inc. (NASDAQ:GNMK) dropped 3.9% during trading on Monday . The stock traded as low as $8.55 and last traded at $8.64, with a volume of 237,143 shares trading hands. The stock had previously closed at $8.99.

GNMK has been the topic of several analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $13.00 target price on shares of GenMark Diagnostics in a report on Friday, July 29th. JPMorgan Chase & Co. raised their target price on GenMark Diagnostics from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, July 29th. Zacks Investment Research upgraded GenMark Diagnostics from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, August 2nd. Finally, Needham & Company LLC assumed coverage on GenMark Diagnostics in a report on Friday, June 17th. They set a “buy” rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.39.

The stock’s market capitalization is $372.75 million. The firm’s 50 day moving average price is $9.63 and its 200 day moving average price is $7.09.

GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Thursday, July 28th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm earned $12.50 million during the quarter, compared to analysts’ expectations of $9.62 million. During the same quarter last year, the firm earned ($0.29) EPS. The business’s revenue for the quarter was up 63.6% compared to the same quarter last year. Analysts predict that GenMark Diagnostics Inc. will post ($1.17) earnings per share for the current fiscal year.

An institutional investor recently raised its position in GenMark Diagnostics stock. Schwab Charles Investment Management Inc. boosted its position in shares of GenMark Diagnostics Inc. (NASDAQ:GNMK) by 4.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 142,024 shares of the company’s stock after buying an additional 5,481 shares during the period. Schwab Charles Investment Management Inc. owned about 0.33% of GenMark Diagnostics worth $1,103,000 at the end of the most recent reporting period.

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.